Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 15 of 16
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
NCT00476177
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
NCT00083031
Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery
NCT00458549
Amifostine for Head and Neck Irradiation in Lymphoma
NCT00136474
Educational Interventions for Patients With DCIS
NCT00148655
Randomized Amifostine For SCCHN
NCT00095927
Preventing Adverse Drug Events With PatientSite
NCT00140504
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
NCT00134654
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
NCT00142181
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
NCT00123851
Natural History Study of Patients With Chronic Myelogenous Leukemia
NCT00429910
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
NCT00137800
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
NCT00134641
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
NCT00084838
rhEndostatin Protein Involving Pediatric Patients With Cancer
NCT00165373
High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma
NCT00165581
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
NCT00136487
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
NCT00098865
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
NCT00123825
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
NCT00144703
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
NCT00146614
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
NCT00052611
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
NCT00136435
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
NCT00136409
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
NCT00165230
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907
Letrozole in Preventing Breast Cancer in Postmenopausal Women
NCT00090857
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
NCT00137852
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
NCT00142155
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
NCT00058487
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
NCT00215501
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
NCT00165217
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
NCT00165438
Prolonged Daily Temozolomide for Low-Grade Glioma
NCT00165360
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
NCT00146549
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
NCT00165464
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
NCT00165386
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
NCT00165451
Preoperative Herceptin and Navelbine for Breast Cancer
NCT00148681
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
NCT00165308
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00047294
Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
NCT00020618
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT00020670
Valdecoxib in Treating Chronic Pain in Cancer Patients
NCT00021996
Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease
NCT00053976
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
NCT00069940
Treatment of Acute Lymphoblastic Leukemia in Children
NCT00165178
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00215514
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00006107
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
NCT00215462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.